@entity14534 : a review of its use in the prevention of @entity64 and systemic XXXX in @entity1 with @entity955 .

@entity1 @entity64 @entity556 @entity548 @entity510 @entity3926 @entity14534 @entity887 @entity955 @entity2210 @entity360 @entity1229
The need for safe, effective, and easily administered and monitored antithrombotic treatments that do not have the issues common to @entity1229 treatment has led to the development of new anticoagulant drugs. @entity14534 (Pradaxa  , Pradax   ) is a prodrug of the direct @entity556 inhibitor @entity3926 , a direct, reversible, potent inhibitor of @entity556 . Dabigatran does not interact with food, and is associated with very few known drug interactions. @entity14534 , at dosages of 110 and 150   mg twice daily, was shown to be noninferior to @entity1229 with regard to the incidence of @entity64 or systemic @entity887 in a large, randomized, partially blinded, multicenter study in a wide spectrum of @entity1 with @entity955 . Moreover, the higher dosage was associated with significantly greater efficacy than @entity1229 in this regard. These results were supported by secondary endpoints and subgroup analyses. In general, @entity14534 is well tolerated, although it is associated with a higher rate of @entity2210 than @entity1229 . Major @entity548 was as common in recipients of the higher dosage as, and less common in recipients of the lower dosage of @entity14534 than, that in recipients of @entity1229 , and @entity510 , life-threatening major @entity548 , and total @entity548 were less common in recipients of either @entity14534 dosage than in @entity1229 recipients. However, the higher dosage of @entity14534 was associated with a higher rate of @entity360 than @entity1229 . The incidence of hepatotoxicity did not significantly differ across treatment groups. In conclusion, @entity14534 150   mg twice daily is more effective than @entity1229 for the prevention of @entity64 and systemic @entity887 in @entity1 with @entity955 , and generally well tolerated, particularly with regard to @entity548 endpoints compared with @entity1229 . It requires more frequent administration than @entity1229 , but provides multiple improvements to various issues associated with @entity1229 administration. Direct comparisons with other new anticoagulant drugs would be beneficial, as would further investigation into the effects in different @entity1 populations, long-term effects, and the @entity360 and @entity2210 observed with @entity14534 treatment. @entity14534 is a promising new option for the prevention of @entity64 and systemic @entity887 in @entity1 with @entity955 .
